A simulation of 2,548 gut transplants identified two “super donors” with near-universal colonization success (Sep 2026, multiple models) Metagenome-scale modeling to assess microbiome metabolic complementarity for precision microbiota transplantation therapies FMT

[IsthmusSIBO]

https://www.tandfonline.com/doi/full/10.1080/19490976.2026.2725403

https://biomesci.com/gut-microbiome-super-donor-fmt-metabolic-model/

The core finding is that a donor's bacteria are more likely to successfully colonize a recipient's gut when their metabolism is different from, not similar to, what the recipient's own gut bacteria are already doing. Also, bigger engraftment scores didn't guarantee symptom relief either; some patients whose gut composition shifted closer to their donor's still did not go into remission, suggesting engraftment alone isn't the whole story of why FMT works or fails.

Click to shrink...

ABSTRACT​

Fecal microbiota transplantation (FMT) holds therapeutic promise beyond recurrent Clostridioides difficile infection, but clinical outcomes remain unpredictable and donor-selection strategies remain limited, in part because the role of donor‒recipient metabolic interactions in shaping the post-FMT community remains poorly understood. Here, we leverage metagenome-scale metabolic modeling to quantify metabolic niche complementarity between donor and recipient microbiomes and predict post-FMT community composition. Using MICOM-derived metabolic models, we show that donor genomes whose metabolic flux profiles are more dissimilar from the recipient community colonize at significantly higher rates in a murine FMT model. In a human IBS trial, the same metric predicted post-FMT community composition via leave-one-out cross-validation and captured known disease-associated alterations in short-chain fatty acid, sulfur, and gas metabolism. We then performed 2,548 in silico FMT simulations between IBS-D/M patients and donors from the OpenBiome biobank to evaluate personalized donor screening, identifying super-donors characterized by high taxonomic diversity, broad metabolic niche coverage, and community interaction networks dominated by cross-feeding rather than competition. Together, these results support metabolic niche complementarity as a potential determinant of post-FMT community composition and provide a mechanistic basis for evaluating donor–recipient metabolic compatibility. This framework offers a scalable approach for generating testable hypotheses for personalized donor selection.

Click to shrink...

What "Super-Donors" Actually Look Like​

Among the 98 candidate donors in the simulation, two stood out as "super-donors," achieving high predicted engraftment across nearly every recipient they were matched with (median engraftment scores of 0.83 and 0.81). These donors weren't just generically healthy: they had unusually high bacterial diversity and metabolisms that were broadly complementary to a wide range of recipients, meaning their gut communities relied heavily on cross-feeding, where different bacterial species trade metabolic byproducts back and forth rather than competing for the same resources. For someone weighing FMT as an option, or already researching donor programs, the practical implication is that "healthy donor" may not be the right bar. A more sophisticated screening process that accounts for a donor's metabolic profile, not just their overall health and diversity, could meaningfully change how well the transplant takes.

Click to shrink...

Many things here about donor quality and matching that @Michael Harrop already has hypothesized and attested to anecdotally. But to me the biggest takeaway is that engraftment ≠ clinical remission.

Some criticisms and limitations additional to the ones originally mentioned:

• the use of a IBS trial with OpenBiome donors.
• AI use for “coding assistance, editorial proofreading, identification of internal inconsistencies between text and figures, and copyediting of the final draft”. Yet, they allege “all scientific content, analysis, interpretation, and writing were performed by the authors. The authors reviewed and take full responsibility for the final manuscript”.
• “While our models use curated GEMs and metagenomic data, they still rely on steady-state assumptions, standardized environmental conditions, and incomplete knowledge of species-level variations in metabolism, which could potentially influence metabolic distance calculations relative to recipient microbiota.”

 

[Asclepius]

"identifying super-donors characterized by high taxonomic diversity, broad metabolic niche coverage, and community interaction networks dominated by cross-feeding rather than competition."

Click to shrink...

That's a remarkable finding considering the results of this study (discussed on the forum here) which found cross-feeding to be highly correlated with disease, and competition to be associated with good health. This study basically says the opposite, at least when it comes to donors.

Maybe there are certain collaborative states in healthy people that aren't harmful but strengthens the biome instead.

 

[IsthmusSIBO]

Maybe there are certain collaborative states in healthy people that aren't harmful but strengthens the biome instead.

Click to shrink...

As in anything related to the microbiome, there is no single obvious answer to anything.

I agree with super donors having both cross-feeding and competitive mechanisms in their microbiome that don’t provoke major dysbiosis. There is no mechanism that totally defines one or the other.

Hell, maybe even those super donors had competition too but because the study didn’t focus on that, they just didn’t report it.

 

[SFBayFMT5]

Some criticisms and limitations additional to the ones originally mentioned:

• the use of a IBS trial with OpenBiome donors.

Click to shrink...

Why is that a limitation? The study was done with the donor characteristics (including microbiome data) known to the researchers, and compared donors with IBS improvement vs. lack of improvement. The criticisms of OpenBiome that I've seen here are that not everyone improves, and in fact some patients get worse, and since patients cannot compare which donors they received it's really impossible to conclude anything. This study got around both of those issues, by looking at who actually improved and what type of donors they received, across a large recipient and donor pool. This is the kind of work that should have been done a long time ago.

That's a remarkable finding considering the results of this study (discussed on the forum here) which found cross-feeding to be highly correlated with disease, and competition to be associated with good health. This study basically says the opposite, at least when it comes to donors.

Maybe there are certain collaborative states in healthy people that aren't harmful but strengthens the biome instead.

Click to shrink...

It's also one of the few studies that shows elevated SCFA production in IBS-D and reduction of SCFA production in recipients who improved as opposed to those who didn't. I've been suspecting for quite a few years now that the general idea in the field that the healthy gut microbiome, and by extension FMT, improves health primarily by increasing SCFA production has major weaknesses. Here we see actual evidence to back up this possibly being a misconception, I'm suspecting due to having access to a dataset where the donor microbiome variability is wide enough to actually ask this question properly. Most other studies used only one or two donors, and in that case the best you can do is speculate that "random" traits of the donor are beneficial if the study was successful, or possibly harmful if the study failed.